Inventiva (NASDAQ:IVA) Shares Gap Up – Time to Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $4.97, but opened at $5.18. Inventiva shares last traded at $5.1250, with a volume of 16,606 shares traded.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on IVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Barclays started coverage on Inventiva in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price objective for the company. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Leerink Partners started coverage on Inventiva in a research report on Monday, January 12th. They issued an “outperform” rating and a $12.00 price objective for the company. Finally, HC Wainwright set a $24.00 price objective on Inventiva and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Price Performance

The company has a 50-day moving average price of $5.83 and a two-hundred day moving average price of $5.33.

Inventiva (NASDAQ:IVA) last issued its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The firm had revenue of $0.01 million during the quarter. On average, research analysts predict that Inventiva S.A. Sponsored ADR will post -1.17 earnings per share for the current year.

Institutional Trading of Inventiva

Several large investors have recently made changes to their positions in the company. Paradigm Biocapital Advisors LP acquired a new stake in shares of Inventiva in the 4th quarter valued at about $18,600,000. ADAR1 Capital Management LLC acquired a new stake in shares of Inventiva in the 4th quarter valued at about $12,601,000. Millennium Management LLC grew its stake in shares of Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after buying an additional 2,540,540 shares during the period. UBS Group AG grew its stake in shares of Inventiva by 28,881.6% in the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after buying an additional 2,634,580 shares during the period. Finally, SymBiosis Capital Partners LLC acquired a new stake in shares of Inventiva in the 4th quarter valued at about $12,090,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.